Semaglutide . acetate

CHF 180.00
In stock
AG-CP3-0032-MC050.5 mgCHF 180.00
AG-CP3-0032-M0011 mgCHF 320.00
More Information
Product Details
Synonyms NN 9535; NNC 0113-0217; Ozempic
Product Type Chemical
Properties
Formula

C187H291N45O59 . C2H4O2

MW 4113.6 . 60.0
Sequence

H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

CAS 910463-68-2 (parent)
Source/Host Chemicals Synthetic.
Purity Chemicals ≥95% (HPLC)
Appearance Solid lyophilized powder.
Solubility Soluble in aqueous solution (5% AcOH) (1mg/ml).
Identity Determined by MS and EA.
InChi Key CQZWIAQBGGIDHL-XFQFMCQFSA-N
Smiles CC[C@@H]([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CC(C)C)=O)CC1=CNC2=C1C=CC=C2)=O)C)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H]([C@H](O)C)NC(CNC([C@@H](NC(C(C)(NC([C@H](CC3=CNC=N3)N)=O)C)=O)CCC(O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)CO)=O)CC(O)=O)=O)=O)CO)=O)CO)=O)CC5=CC=C(C=C5)O)=O)CC(C)C)=O)CCC(O)=O)=O)=O)CCC(N)=O)=O)C)=O)C)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)CCC(O)=O)=O)CC6=CC=CC=C6)=O)C.O=C(C)O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Glucagon-like peptide-1 (GLP-1) receptor agonist.
  • Antidiabetic agent against type 2 diabetes (T2D). Stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner.
  • Longer-acting alternative to liraglutide. Chemically similar to glucagon-like peptide-1 (GLP-1), with two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and derivatized at lysine 26.
  • Antiobesity activity. Reduces energy intake, likely mechanisms for semaglutide-induced weight loss include less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods.
Product References
  1. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide: J. Lau, et al.; J. Med. Chem. 58, 7370 (2015)
  2. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes: S.P. Marso, et al.; N. Engl. J. Med. 375, 1834 (2016)
  3. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity: J. Blundell, et al.; Diabetes Obes. Metab. 19, 1242 (2017)
  4. Semaglutide-the “new kid on the block” in the field of glucagon-like peptide-1 receptor agonists? C. Guja & R. Danciulescu Miulescu; Ann. Transl. Med. 5, 475 (2017) (Review)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.